Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.17−0.04 (-0.12%)
Close on Nov 18, 2026Market cap $6.85BP/E –Yield –
Immunovant free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Immunovant's free cash flow for the twelve months ending Mar 31, 2026 was -$407.32M. For fiscal 2026 it was -$407.32M. The highest annual figure on record is -$28.60M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$407.32M | – |
| FY2025 | Mar 31, 2025 | -$376.63M | – |
| FY2024 | Mar 31, 2024 | -$214.59M | – |
| FY2023 | Mar 31, 2023 | -$188.39M | – |
| FY2022 | Mar 31, 2022 | -$106.37M | – |
| FY2021 | Mar 31, 2021 | -$83.54M | – |
| FY2020 | Mar 31, 2020 | -$53.39M | – |
| FY2019 | Mar 31, 2019 | -$28.60M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$95.07M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$92.33M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$102.52M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$117.41M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$110.84M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$100.57M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$88.84M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$76.38M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$59.85M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$47.23M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$60.09M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$47.42M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$55.82M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$46.49M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$20.22M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$65.86M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$33.07M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$31.97M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$20.09M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$21.23M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$22.59M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$22.84M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$24.26M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$13.85M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$27.49M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$8.33M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$450 | – |
See a number that looks wrong?